MedTrace Logo

The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients

NCT00002385 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2005-06-24

No results posted yet for this study

Summary

To identify doses of fozivudine tidoxil that are well tolerated and produce measurable antiviral activity.

To identify the adverse event profile that defines the maximum tolerated dose. To characterize the single- and multiple-dose pharmacokinetics of fozivudine and its metabolites.

To correlate the adverse event profile and antiviral activity of fozivudine with pharmacokinetic parameters.

Conditions

  • HIV Infections

Interventions

DRUG

Fozivudine tidoxil

Sponsors & Collaborators

  • Boehringer Mannheim

    collaborator INDUSTRY

  • Anderson Clinical Research

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002385 on ClinicalTrials.gov